DMAC

DiaMedica Therapeutics Inc. DMAC

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.5M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-10.14M

Quarter to Jun 30

Free cash flow

$-8.12M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$87.81M total
COOPERMAN LEON G
$24.29M+70.8%
BlackRock, Inc.
$15.86M+21.3%
GEODE CAPITAL MANAGEMENT, LLC
$6.30M+14.6%
MILLENNIUM MANAGEMENT LLC
$5.95M-9.6%
STATE STREET CORP
$4.55M+0.4%
Bleichroeder LP
$2.69M0.0%
VANGUARD CAPITAL MANAGEMENT LLC
$2.50M+6.6%
OSAIC HOLDINGS, INC.
$2.38M+5.8%
NORTHERN TRUST CORP
$2.31M-3.3%
VANGUARD PORTFOLIO MANAGEMENT LLC
$1.77M+23.7%
LPL Financial LLC
$1.64M+3.3%
VANGUARD FIDUCIARY TRUST CO
$1.46M+10.5%
GOLDMAN SACHS GROUP INC
$1.18M+183.5%
CITADEL ADVISORS LLC
$1.03M+0.1%
Squarepoint Ops LLC
$1.02MNew
Bank of New York Mellon Corp
$829.4K+6.1%
MEMBERS WEALTH LLC
$713.7K0.0%
CHARLES SCHWAB INVESTMENT MANAGEMENT INC
$680.7K+9.4%
COBALT CAPITAL MANAGEMENT, INC.
$633.6KNew
Trexquant Investment LP
$595.9K+280.3%
MAGNOLIA CAPITAL ADVISORS LLC
$544.9K0.0%
Diametric Capital, LP
$539.4KNew
GSA CAPITAL PARTNERS LLP
$511.0K+24.0%
Ronald Blue Trust, Inc.
$486.6K0.0%
BANK OF AMERICA CORP /DE/
$406.3K+34.9%
See all 89 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/DMAC

Loading ratio trend…

DMAC key financials by period

Reported revenue, net income and operating margin by fiscal year, from DiaMedica Therapeutics Inc.'s annual filings on SEC EDGAR.

DiaMedica Therapeutics Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2018$500.0K$-5.7M—
Source: DMAC filings on SEC EDGAR →

DMAC insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About DiaMedica Therapeutics Inc. (DMAC): stock profile, AI score and financials

DiaMedica Therapeutics Inc. (DMAC) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. DMAC is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.5m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), DiaMedica Therapeutics Inc. reports net income of $-10.1M, free cash flow of $-8.1M. Top institutional holders of DMAC by reported 13-F value include COOPERMAN LEON G, BlackRock, GEODE CAPITAL MANAGEMENT, based on the most recent SEC filings. DMAC trades on the Nasdaq exchange and files with the SEC under CIK 1401040. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DMAC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for DiaMedica Therapeutics Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1401040 →